April 6, 2026, move the court to be appointed lead plaintiff. The law firm behind the case is urging affected shareholders to ...
The event's highlight features the launch of the Pink Line's 12.3-km Majlis Park-Maujpur-Babarpur corridor and Magenta Line's 9.9-km Deepali Chowk-Majlis Park extension. Serving neighbourhoods like ...
National Interest on MSN
India Is Gradually Weaning Itself Off Russian Arms—and the Kremlin Is Worried
India’s slow shift toward self-reliance in arms manufacturing is a major problem for Russia, already hamstrung by domestic consumption for Ukraine and competition abroad from China.
Nvidia CEO Jensen Huang hints at agentic AI at GTC; a Groq-based LPU could boost inference, defend its moat, and more. Click ...
Performance Trust Capital Partners, LLC served as financial advisor and Hunton Andrews Kurth LLP served as legal counsel to ServBanc Holdco, Inc. Keefe Bruyette & Woods, Inc., a Stifel Company, served ...
Fourth Quarter Revenues Increase 3.1% Year over Year - - Full Year Revenues of $54.9 Million, Net Income of $2.9 Million and ...
In a moment of professional tribute, Dr. Mostafa Madkour presented the "Strategic Partnership Trophy" to both H.E. Eng. Tarek El Molla and Eng. Khaled Abu Bakr, honoring their pivotal roles and ...
The leadership team behind the formation of Greenland Energy Company (“Greenland”) today announced the appointment of Ashiq Merchant as Chief Financial Officer of the post-merger company. Merchant ...
SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...
So hello, and welcome to the Glenveagh Full Year Results 2025 Results Conference Call. Please note, this conference is being recorded. [Operator Instructions] I will now hand you over to your host, ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results